CANDEL THERAPEUTICS, INC. Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value
CANDEL THERAPEUTICS, INC. (CADL) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value of $5.80 million for the 3-month period ending 2021-09-30, per its 10-Q filed 2021-11-12.
Discontinued › Notes › Share-Based Payment Arrangement, Disclosure
us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1 · last filed 2022-05-12
- CANDEL THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, vested in period, fair value for the quarter ending 2021-09-30 was $5.80M, a 580300.00% increase year-over-year.
- CANDEL THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, vested in period, fair value for the quarter ending 2021-06-30 was $100.00K.
- CANDEL THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, vested in period, fair value for the quarter ending 2021-03-31 was $4.97K.
- CANDEL THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, vested in period, fair value for the quarter ending 2020-09-30 was $1.00K.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value 9 month |
|---|---|---|---|
| 2021-09-30 | $5.80M 10-Q · filed 2021-11-12 | $5.90M derived: sum of 2 quarters · filed 2021-11-12 | $6.86M 10-Q · filed 2021-11-12 |
| 2021-06-30 | $100.00K 10-Q · filed 2021-09-08 | $406.00K 10-Q · filed 2021-09-08 | |
| 2021-03-31 | $4.97K 10-Q · filed 2022-05-12 | ||
| 2020-09-30 | $1.00K 10-Q · filed 2021-11-12 | $1.00K derived: sum of 2 quarters · filed 2021-11-12 | $4.00K 10-Q · filed 2021-11-12 |
| 2020-06-30 | $0.00 10-Q · filed 2021-09-08 | $3.00K 10-Q · filed 2021-09-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Sana Biotechnology, Inc. (SANA) | United States | $0.886B | -4.92 |
| Attovia Therapeutics, Inc. (ATTO) | United States | $0.828B | |
| Odyssey Therapeutics, Inc. (ODTX) | United States | $0.960B | |
| Solid Biosciences Inc. (SLDB) | United States | $0.802B | -5.07 |
| Cullinan Therapeutics, Inc. (CGEM) | United States | $0.993B | -5.72 |
| Monte Rosa Therapeutics, Inc. (GLUE) | United States | $1.002B | -12.81 |
| 4D Molecular Therapeutics, Inc. (FDMT) | United States | $0.733B | -4.10 |
| MeiraGTx Holdings plc (MGTX) | United States | $1.061B | 16.10 |
| Vor Biopharma Inc. (VOR) | United States | $1.091B | 1.60 |
| Aura Biosciences, Inc. (AURA) | United States | $0.639B | -5.61 |